| Literature DB >> 24415975 |
Michael Untch1, Bernd Gerber2, Nadia Harbeck3, Christian Jackisch4, Norbert Marschner5, Volker Möbus6, Gunter von Minckwitz7, Sibylle Loibl8, Matthias W Beckmann9, Jens-Uwe Blohmer10, Serban-Dan Costa11, Thomas Decker12, Ingo Diel13, Thomas Dimpfl14, Wolfgang Eiermann15, Tanja Fehm16, Klaus Friese17, Fritz Jänicke18, Wolfgang Janni19, Walter Jonat20, Marion Kiechle21, Uwe Köhler22, Hans-Joachim Lück23, Nicolai Maass24, Kurt Possinger25, Achim Rody26, Anton Scharl27, Andreas Schneeweiss28, Christoph Thomssen29, Diethelm Wallwiener30, Anja Welt31.
Abstract
The International Consensus Conference on the treatment of primary breast cancer takes place every two years in St. Gallen, Switzerland. The panel in St. Gallen is composed of international experts from different countries. From a German perspective, it seems reasonable to interpret the voting results in the light of AGO-recommendations and S3-guidelines for everyday practice in Germany. Consequently, a team of eight breast cancer experts, of whom two are members of the international St. Gallen panel, commented on the voting results of the St. Gallen Consensus Conference (2013). The main topics at this year's St. Gallen conference were surgical issues of the breast and axilla, radio-therapeutic and systemic treatment options, and the clinical relevance of tumour biology. The clinical utility of multigene assays for supporting individual treatment decisions was also intensively discussed.Entities:
Keywords: Adjuvant therapy; Early breast cancer; Multigene signatures; St. Gallen Consensus; Targeted therapy
Year: 2013 PMID: 24415975 PMCID: PMC3728634 DOI: 10.1159/000351692
Source DB: PubMed Journal: Breast Care (Basel) ISSN: 1661-3791 Impact factor: 2.860